دورية أكاديمية
A Randomized Controlled Trial of Nebulized Gentamicin in Non-Cystic Fibrosis Bronchiectasis
| العنوان: | A Randomized Controlled Trial of Nebulized Gentamicin in Non-Cystic Fibrosis Bronchiectasis |
|---|---|
| المؤلفون: | Murray, Maeve P., Govan, John R. W., Doherty, Catherine J., Simpson, A. John, Wilkinson, Thomas S., Chalmers, James D., Greening, Andrew P., Haslett, Christopher, Hill, Adam T. |
| المصدر: | Murray , M P , Govan , J R W , Doherty , C J , Simpson , A J , Wilkinson , T S , Chalmers , J D , Greening , A P , Haslett , C & Hill , A T 2011 , ' A Randomized Controlled Trial of Nebulized Gentamicin in Non-Cystic Fibrosis Bronchiectasis ' , American Journal of Respiratory and Critical Care Medicine , vol. 183 , no. 4 , pp. 491-499 . https://doi.org/10.1164/rccm.201005-0756OCTest |
| سنة النشر: | 2011 |
| المجموعة: | Discovery - University of Dundee Online Publications |
| مصطلحات موضوعية: | QUALITY-OF-LIFE, bronchiectasis, CHRONIC BRONCHIAL INFECTION, TOBRAMYCIN SOLUTION, OBSTRUCTIVE PULMONARY-DISEASE, ANTIBIOTIC-THERAPY, gentamicin, nebulized anibiotics, HEALTH-STATUS, ADULT BRONCHIECTASIS, PSEUDOMONAS-AERUGINOSA, LEICESTER COUGH QUESTIONNAIRE, GEORGES RESPIRATORY QUESTIONNAIRE |
| الوصف: | Rationale: Bronchiectasis is a chronic debilitating disease with few evidence-based long-term treatments. Objectives: A randomized controlled trial assessing the efficacy of nebulized gentamicin therapy over 1 year in patients with non-cystic fibrosis bronchiectasis. Methods: Sixty-five patients were randomized to either twice-daily nebulized gentamicin, 80 mg, or nebulized 0.9% saline, for 12 months. All were reviewed at three-monthly intervals during treatment and at 3 months' follow-up. Measurements and Main Results: At each review the following were assessed: quantitative and qualitative sputum bacteriology; sputum purulence and 24-hour volume; FEV(1), FVC, and forced expiratory flow, midexpiratory phase; exercise capacity; Leicester Cough Questionnaire and St. George's Respiratory Questionnaire; and exacerbation frequency. Fifty-seven patients completed the study. At the end of 12 months' treatment, compared with the saline group, in the gentamicin group there was reduced sputum bacterial density with 30.8% eradication in those infected with Pseudomonas aeruginosa and 92.8% eradication in those infected with other pathogens; less sputum purulence (8.7% vs. 38.5%; P <0.0001); greater exercise capacity (510 [350-690] m vs. 415 [267.5-530] m; P=0.03); and fewer exacerbations (0 [0-1] vs. 1.5 [1-2]; P Conclusions: Regular, long-term nebulized gentamicin is of significant benefit in non-cystic fibrosis bronchiectasis but treatment needs to be continuous for its ongoing efficacy. Clinical trial registered with www.clinicaltrials.gov (NCT 00749866). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://discovery.dundee.ac.uk/en/publications/15f504fa-45d8-47ff-995d-95238c480a1aTest |
| DOI: | 10.1164/rccm.201005-0756OC |
| الإتاحة: | https://doi.org/10.1164/rccm.201005-0756OCTest https://discovery.dundee.ac.uk/en/publications/15f504fa-45d8-47ff-995d-95238c480a1aTest |
| حقوق: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.8151E092 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1164/rccm.201005-0756OC |
|---|